Navigation Links
KemPharm Completes Successful End-of-Phase 2 Meeting with FDA
Date:11/1/2013

NORTH LIBERTY, Iowa, Nov. 1, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today the successful completion of an End-of-Phase 2 meeting with the Food and Drug Administration (FDA) for its lead pain candidate, KP201 (benzhydrocodone hydrochloride and acetaminophen).  Based on the results of the meeting, KemPharm believes the completed and ongoing clinical, non-clinical and CMC development programs will allow for the submission of a New Drug Application (NDA) for KP201 in the third quarter of 2014.

During the meeting, representatives from the FDA reviewed KemPharm's current portfolio of data for KP201, including the recently completed bioequivalence and "steady-state" pivotal clinical studies.  It was determined that the final data package, as proposed by KemPharm, would support a potential 505(b)(2) filing pathway without any additional efficacy, toxicology or safety data being required.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "The positive feedback we received from the Agency re-affirms prior discussions related to our clinical and non-clinical program for KP201 and our plan to pursue an NDA via the 505(b)(2) pathway. Based on their advice, we are extremely confident in our plan to submit an NDA by the third quarter of 2014 and seek potential approval of the first novel pain therapy of the morphine class to be developed in a number of years with an officially recognized new chemical structure."

KP201 is in development for the treatment of acute moderate to moderately severe pain. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induce
'/>"/>

SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. KemPharm, Inc. Appoints Gordon K. "Rusty" Johnson as Chief Operating Officer and Chief Financial Officer
2. KemPharms KP201 Featured at the International Conference on Opioids
3. Micropharma completes development of first microbiome clinical lab test using digital PCR technology
4. Syneron Medical Completes and Summarizes the Multi-site Clinical Study Agreed Upon with FDA for the UltraShape Contour I
5. AIS (American Internet Services) Completes Audit for Title 21 CFR Part 11 Compliance
6. Relmada Therapeutics Inc. Completes $8.0 Million Capital Raise In Series A Financing
7. VIVEX BIOMEDICAL Successfully Completes $7.6 Million Round of Financing
8. Boston Scientific Completes $1.05 Billion Senior Notes Offering
9. SureClinical Completes FDA 21 CFR Part 11 Compliance Audit of SureTrial® eTMF Cloud Edition
10. Eurofins MWG Operon Quality Assurance Group Completes ISO Certifications for Their New Overnight Sequencing Lab
11. Oligomerix, Inc. Completes Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 2015 Regis Technologies announced new ... oncology drug substances. , Regis Technologies is proud to ... Potent Compound Suite (PCS) for 2015. , Regis is ... cGMP facility in Morton Grove, Illinois. The PCS addition ... compounds up to about one kilogram per batch. ...
(Date:2/26/2015)... 2015   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... the Cowen 35 th Annual Health Care Conference on ... Boston .  Lexicon management will provide an overview ... webcast of the presentation will be available through Lexicon,s website ... will be available at www.lexpharma.com until April 3, ...
(Date:2/26/2015)... Feb. 26, 2015 Caris Life Sciences® ... the 2015 Genitourinary Cancers Symposium in ... utility of tumor profiling. Both studies utilized Caris ... service, to identify biomarkers that shed light on ... small cell bladder cancer (SCBC). ...
(Date:2/25/2015)... Feb. 25, 2015 Today, BioMed Realty Trust, ... including a number of promotions and additions to its ... strategy to increase shareholder returns through strategic investments in ... care industry and the innovation sector. ... Griffin is leaving his role as President and ...
Breaking Biology Technology:Regis Extends cGMP Services to Oncology Market 2Lexicon To Present At The Cowen 35th Annual Health Care Conference 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 2Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 3Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 4Tumor Profiling of Metastatic Prostate and Small Cell Bladder Cancers with Caris Molecular Intelligence Yields Insights into Novel and Conventional Therapeutic Options 5BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value 2BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value 3BioMed Realty Announces Realignment To Leverage Depth Of Life Science Real Estate Expertise And Increase Shareholder Value 4
... SANTA CLARA, Calif., March 23, 2011 Finesse ... solutions for life science process applications, has announced ... for interfacing to TruFluor® pH and dissolved oxygen ... continues to be powered by a DeltaV Controller ...
... Neogen Corporation (Nasdaq: NEOG ) announced today ... 2011, which ended Feb. 28, increased 27% from the previous ... to the prior year,s $0.17 per share. ... quarter for the 28-year-old company, compared to the prior year,s ...
... 22, 2011 VENENUM Biodesign, a drug discovery company ... collection to identify hits against its novel disease-based targets ... be exhibiting at the 17th SBS Annual Conference & ... in Orlando, Florida, March 27-31, 2011. VENENUM Biodesign will ...
Cached Biology Technology:Finesse Launches the VirtualTransmitter Module and TruFluor Transmitter Blades for Seamless Integration of Single-Use Sensors Into Bioreactor Control 2Neogen Reports 27% Increase in Quarterly Net Income 2Neogen Reports 27% Increase in Quarterly Net Income 3Neogen Reports 27% Increase in Quarterly Net Income 4Neogen Reports 27% Increase in Quarterly Net Income 5Neogen Reports 27% Increase in Quarterly Net Income 6VENENUM Biodesign to Exhibit at SBS 2
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
(Date:1/22/2015)... , Jan. 15, 2015  BellBrook Labs, a leader ... announced the launch of a TR-FRET (time resolved ... Transcreener UDP Assay, a high throughput screening assay ... assay will allow for sensitive detection of hundreds ...
(Date:1/22/2015)... , Europe,s most prestigious innovation prize ... present a video retrospective of the most exciting and innovative nominations  ... and Sophie Wilson   A different theme ... Starting on 22 January 2015 on   http://www.epo.org/european-inventor   ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... Scientists at the Wake Forest University School of Medicine, ... the Virginia Bioinformatics Institute at Virginia Tech have taken ... of iron metabolism. The team has put together a ... many steps and reactions that constitute iron metabolism. ...
... that a promising antitumor drug could, in theory, shorten patients, ... of researchers that suggests a potentially better option. The study ... of Experimental Medicine (online April 27). Many ... vessels that feed growing tumors. Agents that block a vessel-promoting ...
... a computational biologist and professor with the University of ... Benjamin Franklin Award this week in recognition of his ... open dissemination of science and scientific data. , Bourne ... the annual meeting of the Bioinformatics Organization in Boston. ...
Cached Biology News:Toward a systems biology map of iron metabolism 2Toward a systems biology map of iron metabolism 3A longer lasting tumor blocker 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 2Open access advocate Philip E. Bourne to receive 2009 Benjamin Franklin Award 3
Anti-LC3 Polyclonal Antibody Research Focus: cell surface antigens Storage: -20C Shipping Temperature: +4C...
Mouse monoclonal [SPM325] to Xanthine Oxidase, prediluted ( Abpromise for all tested applications). Antigen: C terminal 358 amino acid fragment of human xanthine oxidase. Entrez Gene ID: 749...
Rabbit polyclonal to Xanthine Oxidase (HRP) ( Abpromise for all tested applications). Antigen: Xanthine Oxidase (from Bovine Buttermilk) Entrez Gene ID: 7498 Swiss Protein ID: P47989...
... Disrupts biological cells for DNA isolation. ... well plates (includes 96 well plate ... lysis across the entire plate length ... Can be used for soil, ...
Biology Products: